Akston Biosciences Corp plans to list on the NYSE American under the symbol AXTN, offering 2,222,222 shares of common stock. It filed a Form S-1 registration statement for an initial public offering on October 8, 2025. As of November 6, 2026, its registration is amended and on file (Form S-1/A, May 4, 2026).
Sell to companies like Akston Biosciences Corp? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
Akston Biosciences Corp filed a Form S-1 registration statement for an initial public offering on 2025-10-08. It has amended it 6 times. As of its latest filing, on 2026-05-04, it has not priced the offering or withdrawn it. Each fact below is quoted from the filing named with it.
What the filings say
Listing
We have applied to list our common stock on the NYSE American under the symbol “AXTN.” We believe that upon the completion of this offering, we will meet the standards for listing on the NYSE American, and the completion of this offering is contingent upon such listing.From the S-1/A filed 2026-05-04
Shares offered
We are offering 2,222,222 shares of our common stock.From the S-1/A filed 2026-05-04
Use of proceeds
We currently intend to use the net proceeds we receive from this offering, together with our existing cash, cash equivalents and short-term investments to complete renovation, build-out, and equipment installation at our new USDA manufacturing facility, manufacture and release pre-license serial batches of AKS-701d at our new USDA manufacturing facility, initiate a pivotal safety and efficacy study in dogs with bladder cancer to support conditional approval of AKS-701d, conduct pilot field efficacy studies in dogs with cancer, dermatitis, and pain using AKS-619d, AKS-699, and AKS-548d, develop manufacturing cell lines for our product candidates, including AKS-548d, complete pilot field…From the S-1/A filed 2026-05-04
Net loss or income
Our net loss for the year ended December 31, 2025, was $28.6 million and our net income for the year ended December 31, 2024, was $3.8 million.From the S-1/A filed 2026-05-04
Timeline
| Filed | What it is | Filing |
|---|---|---|
| 2025-10-08 | Registration statement filed | S-1 |
| 2025-11-17 | Registration statement amended | S-1/A |
| 2025-12-08 | Registration statement amended | S-1/A |
| 2026-01-15 | Registration statement amended | S-1/A |
| 2026-02-18 | Registration statement amended | S-1/A |
| 2026-04-10 | Registration statement amended | S-1/A |
| 2026-05-04 | Registration statement amended | S-1/A |
Check before you invest in Akston Biosciences Corp: the warning signs and who's behind it, free.
Free to see. No signup.
Keep reading
More on Akston Biosciences Corp and the records around it.
Also filing to list on the NYSE American
IPO filings on the NYSE American in Q2 2026, newest first.
- Azitra, Inc. (May 2026)
- Guardian Metal Resources PLC (May 2026)
- SILVER BOW MINING CORP. (May 2026)
- C2 Capital Group, Inc. (Apr 2026)
Watch Akston Biosciences Corp
Get an email when Akston Biosciences Corp files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Akston Biosciences Corp?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Akston Biosciences Corp: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Akston Biosciences Corp covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
7 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Tools for this story
Each opens in a new tab, filled in for Akston Biosciences Corp. With no account yet, you sign up free and land on the result.
Where this comes from
A company that wants to sell shares to the public in the United States files a registration statement with the SEC: Form S-1 for a US company, Form F-1 for a foreign one. It amends that statement as the figures and terms are filled in, usually adding the expected price range shortly before the offering. Once the offering is priced it files its final prospectus under Rule 424(b)(4). A company that decides not to go ahead can ask for the registration statement to be withdrawn on Form RW.
Every row on this page is one of those filings, linked to the filing itself. The facts are the company's own sentences, quoted from the filing named beside each one and never reworded; where no filing states a fact in a sentence that can be read exactly, this page leaves it out. A filing is the company's statement of its plans and its figures, not a verification of them, and nothing here is investment advice.